Canavalia ensiformis lysate stabilizes isolated proteins, enabling autoclaving and maintaining receptor function in glucose biosensors.
Anti-Galectin-9 antibody P4D2 resolves tumor progression inhibition versus immune suppression by blocking Galectin-9 Tim-3 receptor interactions.
Linker molecules bridge IgM antibodies to cell surface markers, enabling targeted receptor clustering and cellular modulation.
Antibodies target LOX-1 receptors to block oxLDL binding, reducing vascular oxidative stress and inflammation.
CO2 plasma treatment modifies substrate surfaces to enable stable biological polymer attachment without chemical crosslinkers.
Gram-positive bacteria host lectin production, reducing costs and complexity compared to E. coli or tobacco plant methods.
Combining ST2 and galectin-3 detection resolves insufficient prediction accuracy by identifying subjects at increased risk of adverse clinical outcomes.
Segmented sialidase treatment exposes terminal sugars for specific lectin binding, resolving low sensitivity of conventional liver markers.